VANI$1.31
$1.39
Chart
Performance
Key Stats
AI VANI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldVivani Medical is a clinical-stage biopharmaceutical company with a focused pipeline on chronic diseases. While it possesses potential thematic alignment with advancements in drug delivery, current financial performance indicates significant losses and no revenue. Technical indicators suggest a volatile trading environment. It is a speculative investment requiring careful risk assessment.
Thematic
Vivani Medical's focus on miniaturized, subdermal drug implants addresses the growing market need for better chronic disease management and medication adherence. The underlying technology has potential, but the company is still in the early stages of development with a long path to commercialization.
Fundamental
Vivani Medical's financials show no revenue, significant operating expenses, and consistent net losses. The company relies on financing to fund its operations, and its cash position is declining relative to its burn rate. The valuation metrics are not applicable due to the lack of revenue and profitability.
Technical
The stock has shown significant recent performance gains, particularly over the last month and year. However, technical indicators on shorter timeframes suggest mixed signals, with some oscillators indicating potential overbought conditions, while moving averages are mixed.
| Factor | Score |
|---|---|
| Chronic Disease Management | 80 |
| Medication Adherence Solutions | 75 |
| Biotechnology Innovation | 50 |
| Therapeutic Focus | 70 |
| Technological Differentiator | 70 |
| Factor | Score |
|---|---|
| Revenue | 0 |
| Profitability | 0 |
| Earnings Per Share (EPS) | 5 |
| Valuation | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Debt Level | 40 |
| Factor | Score |
|---|---|
| Price Trend | 60 |
| Recent Performance | 80 |
| Moving Averages | 65 |
| Oscillators | 40 |
| Volume | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Innovative Drug Delivery Technology
Vivani Medical is developing miniaturized, subdermal drug implants utilizing its NanoPortal technology for chronic disease management and medication non-adherence, addressing a significant unmet need in healthcare.
Promising Product Pipeline
The company has multiple drug implant candidates in development for chronic weight management (NPM-115, NPM-139) and type 2 diabetes (NPM-119), with potential applications in veterinary medicine (OKV-119).
Bearish Points (10)
No Revenue Generation
The company currently has zero reported revenue, indicating a pre-commercial stage with significant financial risk.
Consistent Net Losses
Vivani Medical has reported net losses in all periods available (e.g., -$23.486 million in Q4 2024), reflecting substantial operating expenses and lack of commercialization.
Calendar
January 2020
6
Next Dividend Date
May 2025
14
Next Earnings Date
H: $
A: $
L: $
Profile
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Seasonals
Price Target
4.00 USD
The 39 analysts offering 1 year price forecasts for VANI have a max estimate of 4.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in CNS, developing and commercializing treatments for psychiatric and neurological disorders, including schizophrenia and bipolar depression.
Weight: 92
Direct competitor with a focus on CNS diseases, including schizophrenia and bipolar disorder, overlapping with Vanda's Fanapt.
Weight: 90
Leading player in sleep medicine, a key therapeutic area for Vanda's Hetlioz, offering treatments for narcolepsy and excessive daytime sleepiness.
Weight: 88
Direct competitor in sleep disorders, specializing in treatments for narcolepsy and other sleep-wake conditions, similar to Vanda's Hetlioz.